Table 1 Baseline characteristics of included studies
Study | Year | Design | Country | Population | DOACs type | N total | N DOAC | N Control |
|---|---|---|---|---|---|---|---|---|
Kam et al. | 2022 | Retrospective Cohort | United States | Patients with acute ischemic stroke undergoing IVT with alteplase, either taking NOACs or not taking anticoagulants | Rivaroxaban, Apixaban, or Edoxaban | 163,038 | 2,207 | 160,831 |
Meinel et al. | 2023 | Retrospective Cohort | Europe, Asia, Australia, and New Zealand | Adult patients with ischemic stroke who underwent IVT, either with or without recent use of DOACs | Rivaroxaban, Dabigatran, Apixaban, or Edoxaban | 33,207 | 832 | 32,375 |
Okada et al. | 2022 | Prospective Cohort | Japan | Acute ischemic stroke patients who underwent IVT with alteplase, patients with or without use of DOACs in latest 48Â h | Rivaroxaban, Dabigatran, Apixaban, or Edoxaban | 793 | 40 | 753 |
Seiffge et al. | 2015 | Retrospective Cohort | Europe | Patients with acute ischemic stroke who underwent IVT, IAT, or both | Rivaroxaban, Apixaban, or Dabigatran | 9,016 | 78 | 8,938 |
Xian et al. | 2017 | Retrospective Cohort | United States | Patients with acute ischemic stroke who received thrombolytic therapy, with NOACs or no anticoagulation | Rivaroxaban, Apixaban, or Dabigatran | 41,387 | 251 | 41,136 |
Tasi et al. | 2023 | Retrospective Cohort | Taiwan | Adult patients ≥ 20 years diagnosed with acute ischemic stroke treated with alteplase, with treatment status of NOAC and no oral anticoagulants | Rivaroxaban, Dabigatran, Apixaban, or Edoxaban | 7,301 | 91 | 7,210 |